Alkermes plc
- ALKS
- NASDAQ
- Drug Manufacturers - Specialty & Generic
- CNS/Neuroscience Drugs
- Addiction Treatment Drugs
$42.97
Today +4.25%Quote Oct 19, 2026, 08:00 PM UTC
−0.97%over the last month
Max drawdown −11.5%From 1-month high −2.7%3 months −18.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Alkermes
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Where the money comes from
Q2 2026 revenue $726.9M
- Product$411.7M56.6%
- Vivitrol$124.5M17.1%
- Aristada And Aristada Initio$96.7M13.3%
- L Y B A L V I$94.0M12.9%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Employees
2,050
Founded
1987
Market value
$7.21B
Quote Oct 19
Floor
$42.20
1.8% below price
Resistance
$42.91
Price is above this level
Price vs analyst targets
29 analysts
Lowest target
$50.00Highest target
$65.00
$50.00Highest target
$65.00
- Price $42.97
- Average target $58.29
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 36% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ALKSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free